Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
US-9272024-B2 · Mar 1, 2016 · US
US9981036B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9981036-B2 |
| Application number | US-201615055002-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 26, 2016 |
| Priority date | Dec 12, 2011 |
| Publication date | May 29, 2018 |
| Grant date | May 29, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL 12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. Method of modulating immune response and methods of inducing an immune response against an immunogen are disclosed. Therapeutic and prophylactic vaccination methods are also disclosed.
Opening claim text (preview).
The invention claimed is: 1. A composition for modulating an immune system that comprises a) a nucleic acid sequence that encodes an IL-12 p35 subunit and b) a nucleic acid sequence that encodes an IL-12 p40 subunit, wherein the nucleic acid sequence that encodes the IL-12 p35 subunit is at least 95% identical to SEQ ID NO:1 and encodes a protein at least 95% identical to SEQ ID NO:2, and the nucleic acid sequence that encodes the IL-12 p40 subunit is at least 95% identical to SEQ ID NO:3 and encodes a protein at least 95% identical to SEQ ID NO:4. 2. The composition of claim 1 comprising the nucleic acid sequence that encodes the IL-12 p35 subunit is at least 97% identical to SEQ ID NO:1 and encodes a protein at least 97% identical to SEQ ID NO:2, and the nucleic acid sequence that encodes the IL-12 p40 subunit is at least 97% identical to SEQ ID NO:3 and encodes a protein at least 97% identical to SEQ ID NO:4. 3. The composition of claim 1 formulated for delivery to an individual using electroporation. 4. The composition of claim 1 wherein the nucleic acid sequence that encodes IL-12 p35 subunit is on a different nucleic acid molecule than the nucleic acid sequence that encodes IL-12 p40 subunit. 5. The composition of claim 1 wherein the nucleic acid sequence that encodes IL-12 p35 subunit is on a plasmid and the nucleic acid sequence that encodes IL-12 p40 subunit is on a different plasmid. 6. The composition of claim 1 wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are on the same nucleic acid molecule. 7. The composition of claim 1 wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are on the same plasmid. 8. The composition of claim 1 wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are on the same nucleic acid molecule and operably linked to different promoters. 9. The composition of claim 1 wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are on the same plasmid and operably linked to different promoters. 10. The composition of claim 1 further comprising a nucleic acid sequence that encodes an immunogen. 11. The composition of claim 1 further comprising a nucleic acid sequence that encodes an immunogen from a pathogen selected from the group consisting of: HIV, HPV, HCV, Influenza, Smallpox, Chikungunya, foot and mouth disease virus, Malaria, human cytomegalovirus, human respiratory syncytial virus, and MRSA. 12. The composition of claim 1 wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are incorporated into a viral particle. 13. The composition of claim 1 further comprising a nucleic acid sequence that encodes one or more proteins selected from the group consisting of: IL-15 and IL-28. 14. A method of inducing an immune response against an immunogen comprising administering to an individual, a composition of claim 1 in combination with a nucleic acid sequence that encodes an immunogen in an amount effective to induce an immune response in said individual. 15. The method of claim 14 wherein the composition further comprises a nucleic acid sequence that encodes an immunogen.
for herpes viruses · CPC title
Antivirals · CPC title
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Immunostimulants · CPC title
IL-12 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.